Somapacitan in children born small for gestational age: a multi-centre, open-label, controlled phase 2 study
European Journal of Endocrinology · 2023
DOI: 10.1093/ejendo/lvac008 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Endocrinology, 2023. Verfasst von Anders Juul und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Growth and Reproduction, Copenhagen University Hospital - Rigshospitalet, Copenhagen 2100, Denmark. Hauptthemen laut MEDLINE: Body Height, Human Growth Hormone, Infant, Small for Gestational Age. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objective
Investigate efficacy, safety, and tolerability of 3 once-weekly somapacitan doses compared with daily growth hormone (GH) administration in short children born small for gestational age (SGA).
Design
Randomised, multi-centre, open-label, controlled phase 2 study comprising a 26-week main phase and a 4-year extension (NCT03878446). The study was conducted at 38 sites across 12 countries. 26-week main phase results are presented here. Sixty-two GH treatment-naïve, prepubertal short children born SGA were randomised and exposed; 61 completed the main phase. Three somapacitan doses (0.16 [n = 12], 0.20 [n = 13], 0.24 [n = 12] mg/kg/week) and 2 daily GH doses (0.035 [n = 12], 0.067 [n = 13] mg/kg/day) were administered subcutaneously.
Results
After 26 weeks of treatment, the estimated mean annualised height velocity (HV) was 8.9, 11.0, and 11.3 cm/year for somapacitan 0.16, 0.20, and 0.24 mg/kg/week, respectively, compared to 10.3 and 11.9 cm/year for daily GH 0.035 and 0.067 mg/kg/day. Changes from baseline in HV standard deviation score (SDS), height SDS, and insulin-like growth factor I (IGF-I) SDS showed similar dose-dependent responses. Exposure-response modelling indicated the greatest efficacy correlated with the highest somapacitan exposure. Similar safety and tolerability were demonstrated for all weekly somapacitan and daily GH doses.
Conclusions
Based on the totality of data on improvements in height-based parameters combined with exposure-response analyses, somapacitan 0.24 mg/kg/week appears most efficacious, providing similar efficacy, safety, and tolerability as daily GH 0.067 mg/kg/day in short children born SGA after 26 weeks of treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Growth and Reproduction, Copenhagen University Hospital - Rigshospitalet, Copenhagen 2100, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen 2200, Denmark.
- Division of Endocrinology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45229, United States.
- Clinical Drug Development, Novo Nordisk A/S, Søborg 2860, Denmark.
- Department of Gastroenterology, Nutrition and Endocrinology, Research Institute, Osaka Women's and Children's Hospital, Izumi, Osaka 594-1101, Japan.
- AP-HP, Université Paris Saclay, INSERM, Service d'Endocrinologie et Diabète de l'Enfant, Hôpital Bicêtre Paris Saclay, Le Kremlin-Bicêtre 94270, France.
ORCID-Profile: Anders Juul, Masanobu Kawai, Agnès Linglart, Reiko Horikawa
Förderung
- Novo Nordisk
Zitieren
APA
Juul, A., Backeljauw, P., Højby, M., Kawai, M., Kildemoes, R. J., Linglart, A., Zuckerman-Levin, N., & Horikawa, R. (2023). Somapacitan in children born small for gestational age: a multi-centre, open-label, controlled phase 2 study. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvac008
Vancouver
Juul A, Backeljauw P, Højby M, Kawai M, Kildemoes RJ, Linglart A, et al. Somapacitan in children born small for gestational age: a multi-centre, open-label, controlled phase 2 study. European Journal of Endocrinology. 2023. doi:10.1093/ejendo/lvac008
BibTeX
@article{Juul2023,
author = {Juul, Anders and Backeljauw, Philippe and Højby, Michael and Kawai, Masanobu and Kildemoes, Rasmus Juul and Linglart, Agnès and Zuckerman-Levin, Nehama and Horikawa, Reiko},
title = {Somapacitan in children born small for gestational age: a multi-centre, open-label, controlled phase 2 study},
journal = {European Journal of Endocrinology},
year = {2023},
doi = {10.1093/ejendo/lvac008}
}
EUVIMED